Group items tagged

The UK is far behind comparable nations in spending on medicines and community pharmacies, according to a new analysis by the National Pharmacy Association (NPA). Published today, the report highlights that Britain ranks among the worst countries in the Organisation for Economic Co-operation and Development (OECD) for access to pharmacies, with fewer pharmacies per 100,000 people than countries like Bulgaria, Latvia, Romania, Portugal, Spain, Turkey, France, and many others. On average, a UK pharmacy serves around 5,700 patients, far more than those in France (3,238 patients) and the Republic of Ireland (2,500 patients), where an average pharmacy caters to less than half the number of patients served in the UK. All comparable countries manage fewer patients per pharmacy. The NPA analysis also found that the UK spends less per capita on medicines than nations such as Australia, Ireland, Japan, the US, Spain, Germany, and Italy. Germany spends twice as much as the UK, while the US spends nearly three times more.

The Department of Health and Social Care (DHSC) has published the NIHR's annual report and accounts for 2023/24, highlighting a 4.2 per cent increase in total domestic research spending from the previous year. This increase has allowed the NIHR to improve investments in research funding, infrastructure, and training and career development initiatives. Additionally, the report showcases various research projects that are having a significant impact on people's lives now and in the future. Professor Lucy Chappell, Chief Scientific Advisor at DHSC and Chief Executive of the NIHR, expressed gratitude to all who have contributed to NIHR research over the past year. She stated: "This annual report spotlights where NIHR research has made a tangible difference to people's health outcomes and has contributed to tackling health inequalities. "Through our partnership working, in 2024/25 and beyond, we will continue to ensure that research will be playing its part in driving the Government's Health and Growth Mission to build a health and care system fit for the future."

Don't we all get bored of our monotonous routines? At some point we all need a break in order to enjoy and appreciate life, but living in a city like Delhi makes it almost impossible to find a place which is beautiful and not too crowded. But there's nothing to worry about because we've curated a list of 5 places near Delhi which are perfect for a day spend and are not even crowded.

The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June). The paper details how a financially sustainable VPAS can support widened medicines access to patients. VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. "The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme, data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the association.

Our Totton branch has an incredibly high volume of original pack dispensing, roughly 45,000 items. As we became busier and busier in the dispensary we were finding that our pharmacists, dispensers and other technicians simply didn't have capacity to deliver the services that we needed them to. We all know there is a real emphasis right now on pharmacies doing more services and we knew we had to change the way we operate to survive. So we decided it was time to look into a sound automation solution for our medication dispensing process, one that would allow us to free up the time of the pharmacists and the rest of the team so they could better support patients. After a lot of research we invested in Centred Solutions FLOWRx Hub and InStore solutions which were installed late last year. It provides us with the whole package and has automated our entire dispensing process from picking to packing and labeling to checking. Our situation was quite unique as we bought the system initially for our existing high-volume pharmacy in Totton so the hub and the spoke are actually on the same site. People wouldn't usually look at a hub and spoke solution for that kind of set up but it has allowed us to significantly free up time in store for more services. What it has also done is allow us to look at other opportunities to grow and expand. The pharmacy landscape is changing and there are lots of opportunities coming up. We have found that having your technology and the right infrastructure in place to support your existing footprint before you expand is the ideal way to grow in a safe and controlled way. We never thought that five years ago we would buy another pharmacy, yet we have already bought one and are now in the process of buying two more. I'm not worried about the increase in volume this expansion will bring because I know our technology is going to be able to support it. The pharmacies we are buying are struggling but having our solution already in p

A recent survey conducted by the British Society Attitudes (BSA) and published by the King's Fund and the Nuffield Trust highlighted people's satisfaction with the National Health Services (NHS) to be a new record low since the survey's inception in 1983. The latest findings that are based on the public satisfaction and opinion with the NHS and social care, and funding in the context of prominent national debate about taxation and healthcare spending reveal the satisfaction with the NHS to have dwindled across all services and demographics in 2023. Public contentment has sharply declined, with only 24 per cent expressing satisfaction in 2023, a significant drop from 2020. Factors contributing to this dissatisfaction include prolonged waiting times for GP and hospital appointments, staffing shortages, and perceived inadequate government spending.

UK businesses invested £50 billion in research and development (R&D) in 2023, according to the annual survey report released by the Office for National Statistics (ONS). This marks a £1.4 billion increase (2.9%) compared to the previous year's £48.5 billion. Pharmaceuticals remained the largest contributor to business R&D spending, with £8.7 billion allocated to the sector, accounting for 17.4% of the total R&D expenditure by UK businesses. However, this is slightly down from £8.8 billion in 2022. Other major contributors among product groups included software development with R&D spending at £7.6 billion, and miscellaneous business activities such as technical testing and analysis at £6.9 billion. When measuring the value of R&D performed by industry, the scientific research and development industry emerged as the top performer, with £12.7 billion spent, representing 25.3% of total business R&D.

A new survey has highlighted growing concerns about pharmacists' increasing workload and their often-overlooked role within the healthcare systems. In the survey commissioned by consumer health company Kenvue, over 90 per cent of pharmacists reported a workload increase over the past year, with only 37 per cent considering their current workload sustainable. Their primary concerns include the impact of workload on wellbeing, expanding clinical roles and services, and challenges with staff recruitment and retention. Pharmacists reported spending most of their time advising patients on common ailments such as coughs, colds, pain, and allergies. However, they spend significantly less time on preventive services, which could further reduce pressure on the wider healthcare system. For instance, only seven pharmacists focus primarily on smoking cessation, and just four per cent on oral health. The survey also highlighted pharmacists' sense of being undervalued, with only 22 per cent feeling valued by policymakers, despite their significant contributions to primary care provision.

Despite being more connected than ever, the majority of Europeans are experiencing feelings of loneliness. The STADA Health Report 2024, released on Monday, revealed that over half (52 per cent) of Europeans "always, often or occasionally" feel lonely. Although the younger generation reports the highest levels of overall happiness, they are the ones most affected by this current loneliness epidemic. Nearly two-thirds (63 per cent) of Europeans aged 18 to 35 reported feeling lonely, compared to 41 percent of those aged 55 and older - according to the report, based on a survey of over 46,000 respondents aged 18 to 99 across 32 countries. Extensive screen time is contributing to increased loneliness among younger people. Europeans under the age of 34 are much more likely to spend long hours on their devices (41 per cent) than those aged 35-54 (22 per cent) and those over 55 (13 per cent). The survey found that people who spend a "long" or "fair" amount of time on social media were significantly more prone to feelings of loneliness compared to those who restrict their screen time. Moreover, extensive screen time was also associated with more intense feelings of loneliness.

A recent study suggests that U.S. clinicians spend more time on EHRs than physicians in other countries. This research is also a reflection of administration inconsistencies in the U.S. healthcare system.

"The UK remains genuinely world-leading for life sciences in numerous areas - yet we continue to underperform on our potential," said Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI). His statement is based on recent government data indicating that the UK is not fully capitalizing on its strong historical and institutional advantages in life sciences across a range of economic, health, and research indicators. The latest 'Life sciences competitiveness indicators 2024' report from the government's Office for Life Sciences revealed that while the pharmaceutical industry leads in R&D spending with £9 billion in 2022, representing a fifth of total business investment, the country saw a notable decline in foreign direct investment (FDI), industry clinical trials, and exports. In 2023, FDI dropped by 21 per cent to £0.8 billion, following a trend that saw a 52 per cent decrease over the previous two years, including a £0.9 billion fall in FDI the year prior.

While being out on weekend, why to waste it and why not to use the off at bootcamps weekends in London. If you are much concerned about your wellbeing, then you must join Boot camp At The Place.

It is that time of the year when you spend all your days cursing the scorching summer heat and the harsh rays of the sun. Well, you don't have to worry much as with summers comes the summer vacation when we all take some days off from school, college and work to rewind, relax and chill at a place away from the hustle bustle of your mundane life. So if you are wondering where to go this year to beat the summer heat, here are some cool Indian Places You Need to Visit in India that you must definitely visit this summer vacation:

Omnicell Limited, a wholly owned subsidiary of Omnicell - an American healthcare technology company, has signed an agreement with the shareholders of Hub and Spoke Innovations Limited to acquire Hub and Spoke Innovations. Hub and Spoke Innovations Limited is distributor of the Pharmaself24 prescription collection kiosk in Great Britain. The move will complement Omnicell's total solution technology portfolio for retail pharmacy in the UK, including a pack-pick dispensing robot, automated MDS filling machine and eMAR solution, thereby helping pharmacies to improve workflows and offer a 24/7 access to medications and patient care. It will also help community pharmacies achieve their goals, as they increasingly look at ways to make their businesses more efficient and free up staff to offer more pharmaceutical care and services to patients. In short, the deal would enable Omnicell to offer a wider range of digital technologies to streamline retail pharmacy operations, allowing pharmacists to spend more time with patients and focus on value-added, revenue-generating healthcare services, such as vaccinations.

As part of efforts to streamline spending and enhance resource allocation within the healthcare system, the NHS has chosen to cease providing the free vaccinations for all, which were initially introduced in 2020. Approximately 12 million British citizens will not have access to free flu vaccinations and Covid-19 boosters during the upcoming winter, according to NHS. Furthermore, the NHS plans to defer flu vaccine distribution to October, aiming to heighten protection for those aged 65 and older and other eligible groups in the high-risk winter months. However, this has stirred panic among pharmacies, given their advanced planning based on the initial start date of September 1 for vaccinations. On Tuesday (Aug. 8), the Joint Committee on Vaccination and Immunisation (JCVI) released NHS guidelines indicating that Covid-19 booster shots, starting from autumn, will not be provided to individuals aged 50 to 64 who are in otherwise good health. Similar guidance had already been released for flu, rendering 12 million middle-aged Britons ineligible for free jabs, JCVI said. Prior to the pandemic, influenza vaccinations were available to healthy adults aged over 65, alongside children and younger adults with medical conditions. Amidst the pandemic, the distribution of flu vaccinations was expanded to include individuals aged 50 to 64, in alignment with the criteria for Covid-19 boosters.

Advanz Pharma, alongside London-based private equity firms Cinven and HgCapital, is collectively confronted with an £84 million penalty for inflating the price of the thyroid drug by over 1,000 per cent, soaring from £20 to £248 per package over an eight-year period. The Competition Appeal Tribunal endorsed 'all key aspects' of the Competition and Markets Authority's verdict on the companies' culpability in the case, the CMA has said. Advanz stood as the sole supplier of liothyronine tablets, essential for treating thyroid hormone deficiency, with the cost of a packet of these tablets surging over 12-fold between 2009 and 2017. Although Advanz Pharma currently possesses ownership of the company, its former owners, PE firms Cinven and HgCapital, also bear responsibility for the imposed fine, the CMA said. "NHS annual spending on the tablets in 2006, the year before the implementation of the strategy, was £600,000, but by 2009 had increased to more than £2.3 million and jumped to more than £30 million by 2016," Britain's competition watchdog said.

The British Generic Manufacturers Association (BGMA) has warned of the significant implications for future supply as a result of the crippling VPAS rate. The warning comes after the association's judicial review into the Government's decision to bar it from being a full part of the negotiations for the next five-year VPAS period was dismissed. The voluntary scheme for branded medicines pricing and access (VPAS) is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1%, but in 2023 it has soared to 26.5%. All biosimilars and a proportion of the generics market falls into the scheme.

Approximately 25 million GP appointments and 5 million A&E visits are utilised each year for self-treatable illnesses. If these individuals chose to self-treat using over-the-counter (OTC) medications, the potential savings for NHS could amount to at least £1.7 billion annually, according to a research commissioned by Proprietary Association of Great Britain. The study, conducted by analysts at Frontier Economics, revealed that embracing self-care could bring an additional economic benefit of £350 million annually, as employees would avoid unnecessary time off from work for medical appointments. Apart from the savings resulting from the increased OTC medicine use, the report emphasises the potential benefits of reclassifying more prescription-only medications (POMs). A mere 5 per cent reduction in NHS prescribing levels and spending could lead to an annual cost-saving of £1.4 billion, encompassing both prescription costs and GP appointments, it said. "This substantial amount could greatly alleviate financial pressures on the NHS and offer essential resources for recruiting and training much-needed healthcare professionals."

A bout 15 to 30 per cent of the UK population suffers from hay fever and there has been a definite increase in the number of moderate to severe hay fever sufferers, with sufferers experiencing more frequent and longer seasons. And now that the government has announced its plans for the easing of lockdown, community pharmacists can expect to see many more of their patients presenting with more severe symptoms than usual, as there will be more opportunities to spend time outside and be exposed to higher levels of pollen. Symptoms Common symptoms include sneezing, a runny stuffed up nose, itchy, watery eyes, nasal congestion and a general stuffed up feeling in the nose and throat. Some experience itching around the face and mouth, with an itchy palette, and burning sensation in the throat. Headaches and wheezing can also occur, as well as an overall achy feeling, or build-up of pressure in the facial area. The sinus area can become painful and constant nose blowing can leave sufferers with skin irritation. This can lead to tiredness and affect sleep, which in turn reduces energy.

Assisted living facilities are for people with cognitive decline or those with trouble managing their daily activities like feeding themselves, getting dressed, or bathing. If your loved one can't perform two or more basic daily activities, they become candidates for assisted living. Choosing an assisted living facility goes beyond just signing up and moving in. The choice should be carefully considered because this is where your loved ones will probably spend the rest of their lives. So, when the time comes, you have to consider pertinent things to help you make the right decisions. Levels Of Care Provided By The Assisted Living Facility Assisted living facilities offer varying levels of care which range from lower levels of care to memory care. Having an idea about the different levels of care provided in assisted living facilities will help you ask the right questions. You should be able to know what level best suits your loved one so that their needs can be addressed adequately. For instance, a person who only needs assistance with mobility but can do other things independently will be suited for level 1 care. On the other hand, those who need additional care because they have difficulty remembering things and can't take care of themselves will be better placed in level 3 care.